Development of Potent and Highly Selective Epoxyketone-Based Plasmodium Proteasome Inhibitors
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
Grantová podpora
R01GM061300
NIH HHS - United States
R01 GM061300
NIGMS NIH HHS - United States
R01 AI158612
NIAID NIH HHS - United States
R21AI146387
NIH HHS - United States
R21AI171824
NIH HHS - United States
INV-037899
Bill & Melinda Gates Foundation - United States
R21 AI146387
NIAID NIH HHS - United States
R21AI133393
NIH HHS - United States
R01AI158612
NIH HHS - United States
R21 AI171824
NIAID NIH HHS - United States
R21 AI133393
NIAID NIH HHS - United States
Odkazy
PubMed
36617500
PubMed Central
PMC10894724
DOI
10.1002/chem.202203958
Knihovny.cz E-zdroje
- Klíčová slova
- epoxyketone, inhibition, malaria, plasmodium, proteasome,
- MeSH
- antimalarika * farmakologie MeSH
- inhibitory proteasomu chemie MeSH
- lidé MeSH
- myši MeSH
- Plasmodium falciparum MeSH
- Plasmodium * MeSH
- proteasomový endopeptidasový komplex chemie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antimalarika * MeSH
- inhibitory proteasomu MeSH
- proteasomový endopeptidasový komplex MeSH
Here, we present remarkable epoxyketone-based proteasome inhibitors with low nanomolar in vitro potency for blood-stage Plasmodium falciparum and low cytotoxicity for human cells. Our best compound has more than 2,000-fold greater selectivity for erythrocytic-stage P. falciparum over HepG2 and H460 cells, which is largely driven by the accommodation of the parasite proteasome for a D-amino acid in the P3 position and the preference for a difluorobenzyl group in the P1 position. We isolated the proteasome from P. falciparum cell extracts and determined that the best compound is 171-fold more potent at inhibiting the β5 subunit of P. falciparum proteasome when compared to the same subunit of the human constitutive proteasome. These compounds also significantly reduce parasitemia in a P. berghei mouse infection model and prolong survival of animals by an average of 6 days. The current epoxyketone inhibitors are ideal starting compounds for orally bioavailable anti-malarial drugs.
Malaria World Report, World Health Organization: Geneva, Switzerland, 2020.